Recent Press Releases

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa Monday, 27 July 2015 AstraZeneca today announced that it has entered into a definitive agreement...

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction

THOUSAND OAKS, Calif.

FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication

THOUSAND OAKS, Calif., July 24, 2015 /PRNewswire/ -- Amgen

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for...

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones

CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for full...

ABBVIE REPORTS SECOND-QUARTER 2015 FINANCIAL RESULTS

- REPORTS SECOND-QUARTER ADJUSTED EPS OF $1.08, UP 31.7 PERCENT AND EXCEEDING PREVIOUS GUIDANCE RANGE OF $1.04 TO $1.06 (REPORTS GAAP EPS OF $0.83) - DELIVERS SECOND-QUARTER REVENUE OF $5.475...

Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2015 results, including revenues of $2.6 billion, a 7% increase compared to the second quarter of 2014....

GSK's malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa

24 July 2015 Issued: London, UK WHO will now assess how the world's first malaria candidate vaccine might be used alongside other tools to prevent malaria GSK announced today that the...

Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew

My Diabetes Pit Crew Sweepstakes aims to help people better manage their diabetes

INDIANAPOLIS, July 23, 20

Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma

Filing Based on Data From Phase 3 Head-To-Head ENDEAVOR Study

THOUSAND OAKS, Calif., July 23, 2015 /

Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance

- Revenue increased 1 percent with the inclusion of Novartis Animal Health and higher volume for several products, including Cyramza and Trulicity; these factors were largely offset by the unfavor

Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center

Strong Focus on New Research Collaborations; Up to 130 New Positions to Be Created

INDIANAPOLIS, July 23, 2

TEVA ISSUES STATEMENT

JERUSALEM – JULY 23, 2015 – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today issued the following statement regarding Stichting Preferred Shares Mylan's decision to...

Bristol-Myers Squibb Reports Second Quarter Financial Results

Increases Revenues 7% to $4.2 Billion Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53 Achieves Important Regulatory and Clinical Milestones for Opdivo(nivolumab) ...

Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results

07/23/2015 LAVAL, Quebec, July 23, 2015 /PRNewswire/ -- 2015 Second Quarter Results Total Revenue $2.7 billion; an increase of 34% over the prior year Excluding negative impact of foreign...

Merck Announces Fourth-Quarter 2015 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per...

Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance

Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance - Revenue increased 1 percent with the inclusion of Novartis Animal Health and higher volume for several products, including...

Roche delivers strong performance in the first half of 2015

Group sales up 6% at constant exchange rates, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncology (HER2-positive breast cancer medicines +21%, Avastin +9%, MabThera/Rituxan...

Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease

Results Presented at the Alzheimer's Association International Conference® 2015

INDIANAPOLIS, July 22, 2015

Abbott Reports Second-Quarter 2015 Results

- SECOND-QUARTER ADJUSTED AND GAAP EPS FROM CONTINUING OPERATIONS OF $0.52, ABOVE PREVIOUS GUIDANCE RANGE

ABBOTT PARK, Ill., July 22, 2015